Biblioteca Humberto Rosselli Quijano
Información del autor
Documentos disponibles escritos por este autor (3)
Refinar búsqueda

[artículo]
Título : |
Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder |
Tipo de documento: |
texto impreso |
Autores: |
Marcio Versiani, Autor ; Mohammed Amin, Autor ; Guy Chouinard, Autor |
Fecha de publicación: |
2023 |
Artículo en la página: |
pp. 28-34 |
Idioma : |
Inglés (eng) Idioma original : Inglés (eng) |
Palabras clave: |
Antidepresivos, Trastorno depresivo mayor, Morfolinas. |
Resumen: |
The efficacy and tolerability of reboxetine, a unique selective noradrenaline reuptake inhibitor, were compared with those of placebo in a 6-week, randomized, double-blind study of hospitalized patients with a DSM-III-R diagnosis of major depressive disorder. Fifty-two patients (25 in the placebo group, 27 in the reboxetine group) were included in the efficacy analysis. |
Link: |
./index.php?lvl=notice_display&id=31228 |
in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 1 (Febrero) . - pp. 28-34
[artículo] Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder [texto impreso] / Marcio Versiani, Autor ; Mohammed Amin, Autor ; Guy Chouinard, Autor . - 2023 . - pp. 28-34. Idioma : Inglés ( eng) Idioma original : Inglés ( eng) in Journal of Clinical Psychopharmacology > Año 2000 - Vol. 20 - No. 1 (Febrero) . - pp. 28-34
Palabras clave: |
Antidepresivos, Trastorno depresivo mayor, Morfolinas. |
Resumen: |
The efficacy and tolerability of reboxetine, a unique selective noradrenaline reuptake inhibitor, were compared with those of placebo in a 6-week, randomized, double-blind study of hospitalized patients with a DSM-III-R diagnosis of major depressive disorder. Fifty-two patients (25 in the placebo group, 27 in the reboxetine group) were included in the efficacy analysis. |
Link: |
./index.php?lvl=notice_display&id=31228 |
|

[artículo]
Título : |
Phase IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group |
Tipo de documento: |
texto impreso |
Autores: |
Guy Chouinard, Autor |
Fecha de publicación: |
2022 |
Artículo en la página: |
pp. 1018–1025 |
Idioma : |
Inglés (eng) Idioma original : Inglés (eng) |
Palabras clave: |
Antipsicóticos, Enfermedad crónica, Examen neurológico, Risperidona, Esquizofrenia, Psicología esquizofrénica |
Resumen: |
Since most clinical trials of atypical antipsychotics have been conducted in hospitalized patients, a Phase-IV, multicentre, 8-week, open-label, flexible-dose study was performed to assess the efficacy and safety of risperidone in outpatients with schizophrenia. |
Link: |
./index.php?lvl=notice_display&id=29170 |
in The Canadian Journal of Psychiatry > Año 1998 Vol. 43 - No. 10 (Diciembre) . - pp. 1018–1025
[artículo] Phase IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 Study Group [texto impreso] / Guy Chouinard, Autor . - 2022 . - pp. 1018–1025. Idioma : Inglés ( eng) Idioma original : Inglés ( eng) in The Canadian Journal of Psychiatry > Año 1998 Vol. 43 - No. 10 (Diciembre) . - pp. 1018–1025
Palabras clave: |
Antipsicóticos, Enfermedad crónica, Examen neurológico, Risperidona, Esquizofrenia, Psicología esquizofrénica |
Resumen: |
Since most clinical trials of atypical antipsychotics have been conducted in hospitalized patients, a Phase-IV, multicentre, 8-week, open-label, flexible-dose study was performed to assess the efficacy and safety of risperidone in outpatients with schizophrenia. |
Link: |
./index.php?lvl=notice_display&id=29170 |
|
